Context: Head and neck paragangliomas (HNPGLs) arise from parasympathetic paraganglias and 35% to 45% are hereditary caused by mutations in succinate dehydrogenase (SDH) genes. The connection between SDH and tumor development is unclear. The most accepted hypothesis proposes a central role for the pseudohypoxic (pHx) pathway activated by hypoxia-inducible factor (HIF). Paradoxically, we showed that activation of HIF in HNPGLs is restricted to a subset of HNPGLs lacking SDH mutations. These tumors overexpress HIF-1␣ protein and target genes and the HIFinducible microRNA miR-210 (pHx-HNPGLs).
(SDHB, SDHC, SDHD, and SDHA, SDHAF2) of succinate dehydrogenase (SDH), and TMEM127 (1) . Very rarely, HNPGLs occur in the context of type 2 von HippelLindau (VHL) disease, a condition characterized by a high risk for PGLs that tend to be located in the adrenal gland.
The cause of the sporadic tumors is unknown. As opposed to NF1 somatic loss of function, which has been recently shown to be a frequent event in sporadic PCCs (2, 3) , somatic mutations in other known familial disease genes are rare in sporadic PCC/PGLs (4) . Somatic mutations in HIF-2␣ have also been recently identified in PCC/ PGLs but not HNPGLs (5) . To date, only a few cases of sporadic HNPGLs with somatic mutations have been identified (6, 7) .
The hypoxia-inducible factors (HIFs) are transcriptional activators that regulate genes implicated in angiogenesis, proliferation, and metabolism. pVHL inactivation and succinate accumulation leads to HIF-1␣/HIF-2␣ stabilization (8, 9) . These and other in vivo and in vitro studies in PCC/PGLs support the hypothesis that HIF plays a central role in the familial forms of the disease by inducing the so-called pseudohypoxic (pHx) gene signature (10, 11) . In contrast with this hypothesis, we found that, in the context of HNPGLs, tumors carrying SDH genetic defects do not exhibit activation of pHx pathways (12) . However, increased HIF activity consisting in overexpression of both HIF-1␣-target genes and the HIF-1␣-inducible microRNA miR-210 was found in a subset of non-SDH-mutant HNPGLs. The mechanism of HIF activation in these so-called pHx-HNPGLs remained unknown. In the present study, we uncovered the presence of somatic VHL gene mutations in a subset of pHx-HNPGLs and, therefore, a novel mechanism of tumorigenesis of sporadic HNPGLs. A search for somatic VHL gene mutations in sporadic non-pHx-HNPGLs revealed that this genetic alteration is restricted to pHx-HNPGLs. Thus, pVHL may have a previously unrecognized role in the development of apparently sporadic HNPGLs via activation of the HIF/miR-210 signaling pathway.
Materials and Methods
Tumor samples were obtained from 53 patients with parasympathetic HNPGLs. Clinical and genetic features of patients are described in Table 1 . Mutation analysis was performed by direct sequencing. The presence of large deletions in the VHL gene was analyzed by multiplex ligation-dependent probe amplification (SALSA MLPA P016; MRC Holland) and quantitative PCR (qPCR). RNA isolation and cDNA synthesis were performed as described previously (12) . More detailed descriptions of all methods used in this paper, including a full description of cell culture and treatments, Oncomine metaanalysis, and immunostaining procedures, can be found in Supplemental Materials and Methods, Supplemental Tables 1  and 2 , and Supplemental Figures 1 and 2 (published on The Endocrine Society's Journals Online website at http://jcem.endojournals.org).
Results
Somatic VHL mutations in HNPGLs in association with HIF-1␣/miR-210 gene expression signature VHL gene mutations were analyzed in tumor and blood DNA from 4 patients with pHx-HNPGLs ( Table 1) . A synonymous, likely nonpathogenic, variant c.552C3 T (p.L184L) was found in both tumor and blood DNA in one of the patients (PGL47). Our previous report showed no germline sequence variations in the other 3 patients (12) . However, the sequence analysis of the tumor DNAs performed in the present study revealed somatic mutations in 2 cases. PGL23 carried a c.482G3 A (p.R161Q) missense mutation, and PGL3 harbored an in-frame microdeletion c.227_229delTCT (p.F76del). We did not find VHL somatic variants in the fourth (PGL2) pHx-HNPGL. Somatic gain-of-function mutations in HIF-2␣, which have been identified in sympathetic PGLs as inducer gene of the pseudohypoxic transcription program, were not found in any of the pHx-HNPGLs explored here. We also ruled out the presence of somatic mutations in the oxygen-sensing domains of the HIF-1␣ gene, which could be responsible for HIF-1␣ protein accumulation. Analysis of VHL gene copy number revealed that PGL3 with p.F76del mutation carried a loss of the wild-type VHL allele. No altered VHL gene copy numbers were found in the other 3 pHx-HNPGLs.
The above data suggest that VHL-impaired function could be a mechanism of HIF-1␣/miR-210 activation in pHx-HNPGLs, implying that VHL mutations should not be present in non-pHx-HNPGLs. To check this, we extended the VHL mutation analysis to a series of 49 HNPGLs. This analysis revealed that none of these tumors harbored VHL somatic mutations. Previous studies, performed in 20 of these tumors, showed that none of them overexpressed miR-210 or HIF-1␣ protein, and therefore, they had been classified as non-pHx-HNPGLs (12) . Here, we characterized the remaining 29 tumors and found that all tumors expressed low levels of miR-210, HIF-1␣ protein, and CA9 mRNA, which is one of the most sensitive endogenous sensors of HIF-1␣ activity (Supplemental Figure 2) . Thus, VHL mutation is found only in HNPGLs with activation of HIF-1␣/miR-210 signaling, although not all pHx-HNPGLs carry VHL mutations.
Comparison of the pHx transcriptome of pHxHNPGLs with the transcription profiles reported for other types of cancers, and deposited in the public Oncomine database, revealed that clear cell renal cell carcinomas (ccRCC) is the cancer type that has the most extensive overlap with pHx-HNPGLs (Supplemental Figure 3 and Supplemental Table 3 ). In addition, pHx-HNPGLs share molecular features with VHL-PCC/PGLs but not SDHxor RET/NFI/TMEM127-PCC/PGLs (4, 13) . Collectively, the data support the notion that VHL may be involved in the development of HNPGLs. (14) . We confirmed that 786-O(-) cells do not accumulate HIF-1␣ in normoxia ( Figure 1A) . However, an unexpected faint HIF-1␣ nuclear staining was detected in 786-O(Ϫ) cells when exposed to hypoxia, suggesting that these cells express low amounts of immunoreactive HIF-1␣. As expected, RCC4(Ϫ) cells constitutively accumulated HIF-1␣. No further increase of HIF-1␣ was observed by exposure to hypoxia. In contrast, HIF-1␣ accumulation in RCC4(ϩ) was observed only when cultured under hypoxic but not normoxic conditions. RCC4(Ϫ) cells expressed Ͼ10-fold higher levels of miR-210 and CA9 than RCC4(ϩ) cells ( Figure 1B) . By contrast, the levels of miR-210 were only slightly higher 
Discussion
We report the first identification of somatic VHL mutations in sporadic HNPGLs that are likely involved in their pathogenesis via activation of the HIF-1␣/miR-210 signaling pathway. Ten percent to 20% of families with missense VHL gene mutations are predisposed to develop PCCs (type 2 VHL disease), and 10% to 14% of sporadic PCCs carry somatic mutations in the VHL gene. However, the presence of HNPGLs in patients with VHL disease is extraordinarily rare (15) . Nevertheless, despite the well-established role of VHL in PCC/PGLs, this gene had not, until now, been examined for somatic mutations in sporadic HNPGLs. Here, we identified 2 sporadic HNPGLs harboring activation of the HIF-1␣/miR-210 signaling pathway in which the VHL gene is inactivated via somatic mutation accompanied by loss of heterozygosity in one case. Somatic VHL mutations were not found in HNPGLs lacking activation of HIF-1␣/miR-210 signaling pathway. Remarkably, we found that ccRCC is the tumor type having the most extensive overlap with pHxHNPGLs. A less extensive overlap between pHx-HNPGLs and VHL-but not with SDHx-or RET/NFI/ TMEM127-PCC/PGLs was also identified. These genotype-phenotype correlations support the notion that VHL has a previously unrecognized role in the pathogenesis of some sporadic HNPGLs. We also report here that 2 of the 4 pHx-HNPGLs do not harbor VHL somatic mutations or activating mutations in HIF-2␣ or HIF-1␣. Thus, additional studies to fully characterize pHx-HNPGLs are warranted, with special attention to other genes related to the pVHL-HIF signaling pathway.
VHL mutations have different consequences depending on their location in the protein. Families with germline VHL deletions have low penetrance for PCC and high penetrance for ccRCC (type 1 VHL disease), whereas most families with PCCs (type 2A VHL disease) have missense mutations. Here, we disclosed that 2 types of mutations are present in HNPGL tumor tissues: p.R161Q mutation previously described in type 2 VHL disease (16) disease (17) . This is the first description of a type 1 mutation in PGLs. A previous report showed that PCCassociated VHL mutations do not disrupt the ability of pVHL to regulate HIF-␣, in contrast to ccRCC-associated mutations, which cause HIF-␣ dysregulation. This led to the proposal that deregulation of HIF plays a causal role in the development of VHL-ccRCC but is not strictly required for VHL-PCCs (18) . We found a significantly smaller overlap of genes between pHx-HNPGLs and VHL-PCC/PGLs than between pHx-HNPGLs and ccRCC. Moreover, CA9 is within the top 10 more highly overexpressed genes in pHx-HNPGLs and ccRCC but has not been found overexpressed in VHL-PGL/PCC (4, 18) . In addition, a recent report showed that miR-210 expression is significantly increased in ccRCC with pVHL inactivation and correlates with CA9 mRNA levels (19) . Finally, as observed with most VHL mutations found in ccRCC, the p.R161Q and p.F76del mutations activate the HIF complex (20) . Therefore, the transcriptome of VHLHNPGLs resembles that of ccRCC, suggesting that their pathogenic route is more closely related to ccRCC than to VHL-PCC/PGLs. The relative contribution of HIF-1␣ and HIF-2␣ isoforms in VHL-HNPGL development remains to be fully determined. Clifford et al (20) showed that the 2 mutations identified here block ubiquitylation of the 2 HIF-␣ isoforms. Hence, both or any of the 2 HIF-␣ subunits could play a role in the activation of the pHx transcriptional program of VHL-HNPGLs. However, several lines of evidence suggest a predominant role for HIF-1␣. First, pHx-HNPGLs express higher levels of HIF-1␣ than nonpHx-HNPGLs, whereas none of these groups of tumors showed nuclear accumulation of HIF-2␣ protein. Second, HIF-1␣ knockout prevents miR-210 overexpression by hypoxia (12) . Third, miR-210 overexpression in HNPGLs correlates with upregulation of CA9, a gene whose expression depends on HIF-1 activity. Finally, our work and that of others (21) show that RCC4 cells expressing both HIF-1␣ and HIF-2␣ upregulate miR-210 to a much greater extent than 786-O cells that express only HIF-2␣ (or express very low amounts of HIF-1␣).
VHL mutations were found in 6% of sporadic HNPGLs (2 of 33) included in this study. To date, only a few cases of sporadic HNPGLs with somatic mutations in PGL-susceptibility genes have been identified (6, 7) . Therefore, our data show that although VHL mutations in HNPGLs is not a frequent event, the VHL gene is the most frequent target of somatic mutations so far described in sporadic HNPGLs.
In conclusion, our results suggest that the VHL gene, involved in tumorigenesis in some hereditary and sporadic PCC/PGLs, may be an important player also in sporadic
HNPGLs. This provides the foundation for the development and use of therapeutic approaches that target the pVHL/HIF pathway in a subset of sporadic HNPGLs.
